One of the most notable achievements of 2023 was the approval of a disease-modifying Alzheimer’s drug, representing a breakthrough in the decades-long quest to combat this debilitating condition. Developed by Eisai and Biogen, the amyloid-fighting antibody Leqembi offers hope to millions affected by Alzheimer’s and their families. Moreover, the approval of Leqembi reflects a renewed focus on addressing complex neurological disorders, signaling a shift towards tackling previously untreatable conditions.
The FDA’s approval landscape in 2023 also highlighted the growing prominence of biologic therapies, with nearly half of the newly approved drugs falling into this category. This trend underscores the increasing utilization of advanced biologic modalities and the expanding capabilities of biotechnology in addressing diverse medical needs. Furthermore, the approval of multiple orphan drugs for rare diseases emphasizes the importance of targeted therapies in addressing unmet medical needs within smaller patient populations.
Despite the remarkable progress made in 2023, the FDA faced challenges such as delays due to COVID-19-related constraints and contentious decision-making processes. However, the agency’s commitment to advancing public health and fostering innovation remained steadfast, paving the way for a new era of medical breakthroughs. As we look ahead to 2024, anticipation mounts for further advancements in drug development and the potential for additional groundbreaking therapies to transform patient care and improve outcomes across a spectrum of diseases.
https://www.nature.com/articles/s41587-024-02166-7

Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
